VG
Vishnu Gajanan Nagarsenkar
About Vishnu Gajanan Nagarsenkar
Data last updated:
Vishnu Gajanan Nagarsenkar was a Director at Cfl Pharmaceuticals Limited (2013–2016), Director at Menezes Remedies Limited (2004–2017) and Director at Menezes Pharmaceuticals Limited (2008–2016), and held 1 more directorship. The companies operate in Financial Services, Pharma and Media and Publishing.
Previous companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Cfl Pharmaceuticals Limited U24246GA1981PLC000465 | Director | 15 Jan 2013 | 1981 | ₹202 Cr (FY 2025) | Active |
| Menezes Remedies Limited U52311GA1996PLC002041 | Director | 16 Aug 2004 | 1996 | ₹17.69 Cr (FY 2025) | Active |
| Menezes Pharmaceuticals Limited U24232GA1996PLC002040 | Director | 01 Mar 2008 | 1996 | ₹17.15 Cr (FY 2025) | Active |
| Menezes Marketing Services Private Limited U93000GA1972PTC000147 | Director | 28 Mar 2013 | 1972 | ₹1,755 (FY 2022) | Active |
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Vishnu Gajanan Nagarsenkar
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vishnu Gajanan Nagarsenkar
Vishnu Gajanan Nagarsenkar was first appointed on 16 Aug 2004 as Director at Menezes Remedies Limited. The most recent appointment on record is 28 Mar 2013 at Menezes Marketing Services Private Limited.
Vishnu Gajanan Nagarsenkar held 4 earlier board appointments: Cfl Pharmaceuticals Limited (Director, 15 Jan 2013 to 22 Aug 2016); Menezes Remedies Limited (Director, 16 Aug 2004 to 06 Jan 2017); Menezes Pharmaceuticals Limited (Director, 01 Mar 2008 to 22 Aug 2016); Menezes Marketing Services Private Limited (Director, 28 Mar 2013 to 24 Jan 2019).